化痰定悸汤干预心房颤动:随机双盲单模拟安慰剂对照临床试验方案
本研究为随机双盲单模拟安慰剂对照试验,纳入上海中医药大学附属龙华医院心内科房颤患者,按1:1随机分配接受化痰定悸汤加西药或模拟安慰剂加西药治疗1个月,随后仅用西药随访8周,评估疗效与安全性。
要点
- 化痰定悸汤联合西药治疗房颤(气虚痰浊证)的疗效与安全性待评估。
- 研究采用随机双盲单模拟安慰剂对照设计,评价短期与中期临床疗效。
- 主要结局未在摘要中报告,次要结局包括超声心动图、焦虑抑郁量表等。
核心结论
- 本研究将评估化痰定悸汤联合西药治疗心房颤动(气虚痰浊证)的疗效与安全性,为中西医结合治疗提供临床证据。
研究设计与样本
- 采用随机双盲、单模拟、安慰剂对照的研究方法,通过中央控制计算机生成的简单 randomization 方案按1:1比例分配参与者。
- 参与者来自上海中医药大学附属龙华医院心内科门诊和住院心房颤动患者,服药1个月后评估疗效,随后仅接受西药治疗并随访8周。
- 评估在基线、随机化后第4周和第12周进行。
主要发现
- 原文未报告研究结果,仅描述研究方案。
关键数值与推荐
- 参与者服药1个月后评估疗效,随后不接受中药、仅接受西药治疗并随访8周。
- 次要结局包括超声心动图、汉密尔顿焦虑量表、汉密尔顿抑郁量表、抗心律失常西药增减率、MOS 36项短期健康调查、N端前激素B型利钠肽水平和中医证候积分。
- 整个试验期间监测不良事件。
临床怎么用
- 本研究旨在为化痰定悸汤联合西药治疗心房颤动提供短期和中期临床疗效的医学证据,为后续临床开发与应用奠定基础。
局限性
- 原文未报告研究的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atrial fibrillation (AF) is one of the most common cardiac arrhythmias and can lead to heart failure (HF), stroke, pulmonary embolism (PE), and other complications, seriously affecting people's quality of life and health. Western medicine is limited in the treatment of AF, while Traditional Chinese Medicine (TCM) has unique advantages, such as less side effects, low toxicity, long effect duration, and high compliance. The prescription of HTDJ is a common prescription for the treatment of atrial fibrillation in Longhua Hospital, Shanghai University of Traditional Chinese Medicine. It has been used for many years and has a large number of clinically effective cases. It has a good clinical application prospect, but there is a lack of effective evaluation of its clinical efficacy. METHOD: This study adopts a randomized double-blind, single-simulated, placebo-controlled research method. Participants were randomly assigned in a 1:1 ratio through a centrally controlled, computer-generated, simple randomization schedule. Participants would take the medicine for 1 month, and the curative effect would be evaluated. Subsequently, the participants would not take TCM and only receive western medicine treatment. They would be followed up for another 8 weeks, and a clinical evaluation would be conducted. The secondary outcomes include echocardiography, Hamilton Anxiety Scale, Hamilton Depression Scale, rate of increase and decrease of anti-arrhythmia western medicine, the MOS 36-item short-form health survey, N-terminal-pro hormone B-type natriuretic peptide level, and integral TCM syndrome score. Adverse events will be monitored throughout the trial. Cases are from outpatient and inpatient with atrial fibrillation in the Cardiology Department of Longhua Hospital. Evaluations will be conducted at baseline and at weeks 4 and 12 after randomization. DISCUSSION: In this study, the efficacy and safety of HTDJ plus western medicine in the treatment of atrial fibrillation (qi deficiency and phlegm opacities) will be evaluated, so as to provide medical evidence of short-term and medium-term clinical efficacy for the treatment of atrial fibrillation with integrated traditional and western medicine and lay a foundation for further clinical development and application. TRIAL REGISTRATION: ClinicalTrials.gov ChiCTR2000030517 . Registered on March 5, 2020, with the Chinese Clinical Trial Registry.
引用
- Xiao Y, Wang X, Yang J, et al. Huatan Dingji Decoction intervening in atrial fibrillation: protocol for a randomized double-blind single-simulated placebo-controlled clinical trial. Trials. 2021. PMID: 34635144. doi:10.1186/s13063-021-05522-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。